Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea

J Korean Med Sci. 1995 Oct;10(5):314-7. doi: 10.3346/jkms.1995.10.5.314.

Abstract

The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Bacterial / blood
  • Antigens, Bacterial / immunology
  • Child
  • Evaluation Studies as Topic
  • Humans
  • Polysaccharides, Bacterial / immunology*
  • Salmonella typhi / immunology*
  • Typhoid Fever / prevention & control
  • Typhoid-Paratyphoid Vaccines / adverse effects
  • Typhoid-Paratyphoid Vaccines / immunology
  • Typhoid-Paratyphoid Vaccines / therapeutic use*

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Polysaccharides, Bacterial
  • Typhoid-Paratyphoid Vaccines
  • capsular polysaccharide, Salmonella